FDA tirzepatide ‘reconsideration’ period extended Yesterday, on the deadline FDA was to report back...
Tirzepatide may no longer be on FDA’s shortage list, but many of you know that Mounjaro and Zepbound are still not available in quantities needed to meet patient demand. In fact, tirzepatide injection remains on the American Society of Health-System Pharmacists shortage list. That’s because ASHP’s is much more accurate than FDA’s, relying on real-world, real-time data at the national and regional levels, while FDA can mostly only take drugmakers at their word about supplies.
The disconnect between the FDA’s position and reality is frustrating for both pharmacists and patients. That’s why we need your patients to reach out to FDA and tell the agency what’s really happening. We’ve made it easy for them to do that — and easy for you to tell them.
Patients can go to compounding.com/tellfda, scroll down the page, and click a link to a simple, two-minute form to weigh in with FDA. We’ve provided a sample message, but patients can tell their own story — either way, it’ll be sent automatically to the correct office within the agency.
We’ve also made it easy for you to spread the word with bag-stuffers you can hand out (4x6 and 3x8) to your GLP-1 patients that includes a QR code they can use to go right to that message page to send a message.
The more people who tell the FDA about their issues getting Mounjaro or Zepbound, the clearer the picture will be. Help spread the word!
